Boston Scientific (BSX)DSM Capital Partners LLC reduced its stake -52K shares

512K

Shares reported · -52K vs prior quarter

0.37%

Disclosed portfolio weight

$21.9M

Reported value

Holdings as of

Jun 30, 2026

Filed

Aug 3, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Nov 4, 2025Federal contract · $601K obligatedDepartment of Veterans Affairs awarded Boston Scientific: $601K obligated to date
2. Dec 23, 2025Federal contract · $493K obligatedDepartment of Veterans Affairs awarded Boston Scientific: $493K obligated to date
3. Mar 27, 2026CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
4. May 11, 2026CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
5. May 19, 2026CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
6. May 29, 2026CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
7. Jun 4, 2026CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000
8. Jun 5, 2026Congress · 1 personMembers of Congress: 1 purchase, 1 sale
9. Jul 14, 2026FDARecall: Suture Cinch Long 1pk. Endoscopic tissue approximation device.
10. Jul 16, 2026Federal contract · $608K obligatedDepartment of Veterans Affairs awarded Boston Scientific: $608K obligated to date
11. Jul 21, 2026Company filing · Form 8-K · RestructuringAnnounced job cuts, closures or a restructuring“On July 21, 2026, the Board of Directors of Boston Scientific Corporation (the “Company”) approved a new global restructuring program (the “2026 Restructuring Plan”).”
12. Jul 22, 2026FDARecall: Boston Scientific Corporation StoneSmart Connect Console Contents: (1) Power Cord, (1) Power Adaptor, (1)DVI Cable, (1) DVI to HDMI Cable, (1) DisplayPort Cabl…
13. Jul 24, 2026FDAFDA device clearance: TheraSphere 360™ Y-90 Management Platform
14. Jul 24, 2026FDAFDA device clearance: OBSIDIO Conformable Embolic
15. Jul 24, 2026FDAFDA device clearance: FARADRIVE™ Steerable Sheath (M004PF21M402)
16. Jul 29, 2026Company filing · Form 8-K · ResultsReported its results
17. Jul 31, 2026InsiderDirector purchased ~$227K of BSX shares in the open market
18. Aug 3, 2026Insider · 2 peopleInsiders: 2 purchases (~$9.1M)

What came next

1. Aug 4, 2026FDAFDA device clearance: Navigator™ Flex Ureteral Access Sheath Set
2. Aug 4, 2026Insider · 3 insiders in a week, 7th time since 2006Director purchased ~$6.8K of BSX shares in the open market
3. Aug 5, 2026Insider · 3 insiders in a week, 7th time since 2006Director purchased ~$100K of BSX shares in the open market
4. Aug 6, 2026FDARecall: LUX-Dx, LUX-Dx II, LUX-Dx II+ Insertable Cardiac Monitor System, SERVER SW LAT CLARITY DS US, Model Number 7260, All Versions (Current 7.8)
5. Aug 6, 2026FDARecall: LUX-Dx, LUX-Dx II, LUX-Dx II+ Insertable Cardiac Monitor System, SERVER SW LAT CLARITY DS ANZ, Model Number 7248, All Versions (Current 7.7)
6. Aug 6, 2026FDARecall: LUX-Dx, LUX-Dx II, LUX-Dx II+ Insertable Cardiac Monitor System, SERVER SW LAT CLARITY DS EU, Model Number 7246, All Versions (Current 7.7)
7. Aug 6, 20265% stakeFMR LLC reported a passive stake (13G) of 3.1%
8. Aug 12, 2026FDAFDA device clearance: EluPro Antibiotic-Eluting BioEnvelope
9. Aug 18, 2026CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
10. Aug 21, 2026FDAFDA device clearance: AVVIGO™+ Multi-Modality Guidance System
11. Aug 24, 2026FDARecall: Imager II Angiographic Catheters M001314001 IMAGER II/5/ST/65/038 BX5; M001314011 IMAGER II/5/ST/100/038 BX5; M001314021 IMAGER II/5/ST/65/035 BX 5; M001314031…
12. Aug 25, 2026Insider · 13 days before an 8-KDirector purchased ~$100K of BSX shares in the open market
13. Aug 26, 2026FDAFDA device clearance: LithoVue Elite Digital Flexible Ureteroscope System
14. Aug 31, 2026CongressDisclosed sale of BSX — reported range $15,001 - $50,000
15. Sep 3, 2026FDAFDA device clearance: Rezum System
16. Sep 3, 2026Congress · 1 personMembers of Congress: 3 sales
17. Sep 4, 2026CongressDisclosed partial sale of BSX — reported range $50,001 - $100,000
18. Sep 7, 2026Company filing · Form 8-K · Cyber incidentReported a cybersecurity incident“As previously disclosed in a Current Report on Form 8-K filed on August 26, 2026 with the Securities and Exchange Commission, on August 25, 2026, Boston Scientific Corporation (the “ Company ”) identified a cybersecurity incident that affected certain of its information technology systems and resulted in a global disruption to the Company’s operations.”
19. Sep 9, 2026CongressDisclosed sale of BSX — reported range $50,001 - $100,000
20. Sep 11, 2026FDAFDA device clearance: SpaceOAR Flex™ System

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Boston Scientific

For Boston Scientific, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 9 Congress trade reports, 64 fund holdings reports (13F) and 8 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BSX page.

How this filing works

• SEC Form 13F

Other disclosures at Boston Scientific

• USAspending.gov award recordOct 1, 2026
• USAspending.gov award recordOct 1, 2026
• USAspending.gov award recordOct 1, 2026
• USAspending.gov award recordOct 1, 2026
• USAspending.gov award recordOct 1, 2026
• House Clerk periodic transaction reportSep 25, 2026

Everything OQRO holds on this company is on its BSX page.